Compare PIM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PIM | KZIA |
|---|---|---|
| Founded | 1988 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 125.6M |
| IPO Year | N/A | 2002 |
| Metric | PIM | KZIA |
|---|---|---|
| Price | $2.99 | $5.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.22 |
| AVG Volume (30 Days) | 63.3K | ★ 241.7K |
| Earning Date | 01-01-0001 | 12-01-2026 |
| Dividend Yield | ★ 8.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $258.04 |
| P/E Ratio | $60.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.95 | $4.86 |
| 52 Week High | $3.41 | $17.40 |
| Indicator | PIM | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 28.38 |
| Support Level | $2.96 | $4.86 |
| Resistance Level | $3.21 | $14.85 |
| Average True Range (ATR) | 0.04 | 0.68 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 0.00 | 9.86 |
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.